Hostname: page-component-8448b6f56d-m8qmq Total loading time: 0 Render date: 2024-04-25T06:48:32.080Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment of non-melanoma superficial skin cancer with custom-made wax moulds using Iridium-192 high-dose-rate brachytherapy source

Published online by Cambridge University Press:  24 August 2017

Kamran Ali Shah ,
Habib Ahmad ,
Muhammad Rauf Khatak ,
Misbah Ahmad ,
Nabila Javed ,
Syed Jawad Ali Shah  and
Wajeeha Shaheen
Kamran Ali Shah*
Affiliation:
Institute of Radiotherapy and Nuclear Medicine (IRNUM), University Campus Peshawar, KPK, Pakistan
Habib Ahmad
Affiliation:
Institute of Radiotherapy and Nuclear Medicine (IRNUM), University Campus Peshawar, KPK, Pakistan
Muhammad Rauf Khatak
Affiliation:
Institute of Radiotherapy and Nuclear Medicine (IRNUM), University Campus Peshawar, KPK, Pakistan
Misbah Ahmad
Affiliation:
Institute of Radiotherapy and Nuclear Medicine (IRNUM), University Campus Peshawar, KPK, Pakistan
Nabila Javed
Affiliation:
Institute of Radiotherapy and Nuclear Medicine (IRNUM), University Campus Peshawar, KPK, Pakistan
Syed Jawad Ali Shah
Affiliation:
Institute of Radiotherapy and Nuclear Medicine (IRNUM), University Campus Peshawar, KPK, Pakistan
Wajeeha Shaheen
Affiliation:
Institute of Radiotherapy and Nuclear Medicine (IRNUM), University Campus Peshawar, KPK, Pakistan
*
Correspondence to: Kamran Ali Shah, Institute of Radiotherapy and Nuclear Medicine (IRNUM), University Campus Peshawar, KPK 25000, Pakistan. Tel: +92 91 9221223. Fax: +92 91 9222154-58. E-mail: kamran78phy@gmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Introduction

In non-melanoma skin cancer—that is, basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)—brachytherapy treatment is preferred over surgical excision because of cosmetic reasons, acceptability and preference of patients.

Material and methods

Moulds are prepared of wax to match the size of the lesion. This represents the area to be considered in treatment planning. A total of 85 patients who had either SCC or BCC were treated, and all these patients were classified on the basis of age, gender and origin.

Results

Patients were treated with 39 Gy in 13 fractions (biological effective dose=50·7 Gy). In 52 BCC patients, treatment achieved excellent cosmetic results in 49 cases, with 17 of these patients experiencing Grade-1 skin reactions related to treatment in the first 24 weeks of follow-up. A single patient experienced Grade-II hyper-pigmentation reaction in the third week. In 33 SCC patients, treatment achieved excellent cosmetic results in 28 cases, with 17 of these patients experiencing Grade-I reaction in the first 36 weeks after treatment. Among the remaining four patients, only one developed Grade-II hypo-pigmentation and one patient experienced tumour recurrence near the primary site. The overall outcome efficacy of the treatment was 98·8%.

Findings

The treatment outcome not only enhances our confidence in brachytherapy but also improves the patient’s satisfaction regarding cosmetic results and curative output achieved by avoiding a surgical procedure for non-melanoma skin cancers.

Keywords

BCCIridium-192 brachytherapynonmelanoma skin cancerSCCsurface wax mould
Type
Original Articles
Information
Journal of Radiotherapy in Practice , Volume 17 , Issue 1 , March 2018 , pp. 53 - 59
Check for updates
Copyright
© Cambridge University Press 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Lomas, A, Leonardi-Bee, J, Bath-Hextall, F A. Systematic review of worldwide incidence of non melanoma skin cancer. Br J Dermatol 2012; 166: 1069–1080.Google Scholar
2. Eisemann, N, Waldmann, A, Geller, A C et al. Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence. J Invest Dermatol 2014; 134 (1): 43–50.Google Scholar
3. Mohs, F E. Chemosurgery: microscopically controlled surgery for skin cancer--past, present and future. J Dermatol Surg Oncol 1978 Jan; 4(1): 41–54.Google Scholar
4.American academy of Dermatology. SkinCancerNet: What is skin cancer? Schaumberg, IL: American academy of Dermatology, 2012. http://www.skincarephysicians.com/skincancernet/whatis.html/ Accessed on 17th March 2012.Google Scholar
5. Caresana, G, Giardini, R. Dermoscopy-guided surgery in basal cell carcinoma. J Eur Acad Dermatol Venereol 2010; 24: 1395–1399.Google Scholar
6. Tormo, A, Celada, F, Rodriguez, S, Botella, R, Ballesta, A. Non-melanoma skin cancer treated with HDR Valencia applicator: clinical outcomes. J Contemp Brachytherapy 2014; 6 (2): 167–172.Google Scholar
7. Wong, J R, Wang, C C. Radiation therapy in the treatment of cutaneous malagnencies. Clin Dermatol 2011; 19: 348–353.Google Scholar
8. Graneo, D, Perez-Calytayud, J, Ballester, F, Ouhib, Z. Radiation leakage study for Valencia applicators. Phys Med 2013; 29: 60–64.Google Scholar
9. Delishaj, D, Laliscia, C, Manfredi, B et al. Non-melanoma skin cancer treated with high-dose rate brachytherapy and Valencia applicator in elderly patients: a retrospective case series. J Contemp Brachytherapy 2015; 7: 437–444.Google Scholar
10. Lliso, F, Graneo, D, Perez-Caltayud, J, Carmoan, V, Pujades, M C, Ballester, F. Dosimetric evaluation of internal shielding in a high dose rate skin applicator. J Contemp Brachytherapy 2011; 3: 32–35.Google Scholar
11. Lasota, J, Kabacinska, R, Makarewicz, R. Dose estimation for different skin models in interstitial breast brachytherapy. J Contemp Brachytherapy 2014; 6: 200–207.Google Scholar
12. Kohler-Brock, A, Prager, W, Pohlmann, S, Kunze, S. The indications for the results of HDR after loading therapy in the disease of the skin and mucosa with standardized surface applicators (the Leipzig Applicator). Strahlenther Onkol 1999; 175: 70–174.Google Scholar
13. Prakash, S K, Srinivas, M. Brachytherapy for face, neck basal cell carcinoma. IOSR-JDMS 2016; 15 (10): 31–34.Google Scholar
14. Alam, M, Nanda, S, Mittal, B B, Kim, N A, Yoo, S. The use of brachytherapy in the treatment of nonmelanoma skin cancer: a review. J Am Acad Dermatol 2011; 65: 377–388.Google Scholar
15.US Department of Health and Human Services, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03. Washington, DC: US Government Publishing Office, 14th June 2010.Google Scholar
16. Bhatnagar, A. Non melanoma skin cancer treated with electronic brachytherapy results at 1 year. J Brachytherapy 2013; 12: 134–140.Google Scholar
17. Gauden, R, Pracy, M, Avery, A M, Hodgetts, I, Gauden, S. HDR brachytherapy for superficial non‐melanoma skin cancers. J Med Imaging Radiat Oncol 2013; 57: 212–217.Google Scholar